Massey Quick & Co. LLC lifted its stake in Allergan PLC. (NYSE:AGN) by 334.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 500 shares of the company’s stock after purchasing an additional 385 shares during the quarter. Massey Quick & Co. LLC’s holdings in Allergan PLC. were worth $122,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Allergan PLC. by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 22,835,689 shares of the company’s stock worth $5,551,128,000 after purchasing an additional 482,220 shares in the last quarter. Northern Trust Corp boosted its position in shares of Allergan PLC. by 8.8% in the 2nd quarter. Northern Trust Corp now owns 4,492,944 shares of the company’s stock worth $1,092,189,000 after purchasing an additional 364,722 shares in the last quarter. Veritas Asset Management LLP bought a new stake in shares of Allergan PLC. in the 1st quarter worth approximately $761,339,000. Edgewood Management LLC boosted its position in shares of Allergan PLC. by 7.0% in the 1st quarter. Edgewood Management LLC now owns 2,704,211 shares of the company’s stock worth $646,090,000 after purchasing an additional 178,055 shares in the last quarter. Finally, Epoch Investment Partners Inc. boosted its position in shares of Allergan PLC. by 3.8% in the 1st quarter. Epoch Investment Partners Inc. now owns 2,013,415 shares of the company’s stock worth $481,045,000 after purchasing an additional 73,081 shares in the last quarter. 82.03% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have recently commented on the company. Mizuho reissued a “buy” rating and issued a $267.00 price target on shares of Allergan PLC. in a research report on Wednesday, August 2nd. Royal Bank Of Canada set a $285.00 price objective on shares of Allergan PLC. and gave the stock a “buy” rating in a report on Thursday, August 3rd. Wells Fargo & Company boosted their price objective on shares of Allergan PLC. to $278.00 and gave the stock an “outperform” rating in a report on Thursday, August 3rd. Deutsche Bank AG restated a “buy” rating and issued a $273.00 price objective (up from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. Finally, Vetr upgraded shares of Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 price objective for the company in a report on Monday, June 26th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $271.64.

Allergan PLC. (AGN) opened at 206.75 on Friday. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The company has a 50-day moving average of $218.50 and a 200 day moving average of $233.15. The company has a market cap of $69.12 billion, a P/E ratio of 6.30 and a beta of 1.15.

Allergan PLC. (NYSE:AGN) last released its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. During the same quarter in the previous year, the company earned $3.35 earnings per share. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. Analysts anticipate that Allergan PLC. will post $16.21 earnings per share for the current year.

Allergan PLC. declared that its board has authorized a share repurchase plan on Monday, September 25th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to buy up to 2.8% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Friday, August 18th were issued a $0.70 dividend. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a yield of 1.35%. Allergan PLC.’s payout ratio is 9.95%.

TRADEMARK VIOLATION WARNING: This piece was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.watchlistnews.com/massey-quick-co-llc-has-122000-stake-in-allergan-plc-agn/1614947.html.

Allergan PLC. Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.